The primary long-term objective is to provide the compounds and formulations needed for testing in the Program Projects. Specifically the aims will be to: 1. Optimize synthesis of SAMMA to produce a consistent product for testing. 2. Develop analytical methods for SAMMA. 3. Synthesize derivatives of SAMMA to assess structural requirements for activity. 4. Identify and isolate structural isomers of SAMMA and/or its most active derivative. 5. Produce formulations of SAMMA or related compounds as needed for biological testing. SAMMA is synthesized by the reaction of mandelic acid with sulfuric acid. Adequate amounts of SAMMA are available for initiating studies, however, it will be required to synthesize additional quantities of well-characterized SAMMA to complete the proposed Projects. Derivatives for SAMMA will be synthesized for structure activity investigations. Further structural isolations and investigations including isomer identification and isolation will be guided by biological activity testing to maximize biological activity while maintaining appropriate physical/chemical characteristics which lend themselves to an inexpensive and readily formulated product. The synthesis and analytical requirements will be achieved by utilizing commercial laboratories equipped to perform the required work in the most expeditious and cost beneficial manner. It will also greatly facilitate the movement of SAMMA from the laboratory to scale up for later high quantity requirements for clinical trials and commercialization. This work will be closely monitored by the Core B Principal Investigator and a consultant who have been involved with the synthesis, scale-up and analytical analysis of the compound since it was initially prepared.

National Institute of Health (NIH)
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZHD1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mount Sinai School of Medicine
New York
United States
Zip Code
Anderson, Robert A; Feathergill, Kenneth A; Chany 2nd, Calvin J et al. (2009) Nitric oxide-dependent human acrosomal loss induced by PPCM (SAMMA) and by nitric oxide donors occurs by independent pathways: basis for synthesis of an improved contraceptive microbicide. J Androl 30:168-82
Mesquita, Pedro M M; Wilson, Sarah S; Manlow, Philippe et al. (2008) Candidate microbicide PPCM blocks human immunodeficiency virus type 1 infection in cell and tissue cultures and prevents genital herpes in a murine model. J Virol 82:6576-84
Patel, Sarju; Hazrati, Ehsan; Cheshenko, Natalia et al. (2007) Seminal plasma reduces the effectiveness of topical polyanionic microbicides. J Infect Dis 196:1394-402
Anderson, Robert A; Feathergill, Kenneth A; Waller, Donald P et al. (2006) SAMMA induces premature human acrosomal loss by Ca2+ signaling dysregulation. J Androl 27:568-77
Chang, Theresa L; Vargas Jr, Jesus; DelPortillo, Armando et al. (2005) Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity. J Clin Invest 115:765-73
Scordi-Bello, Irini A; Mosoian, Arevik; He, Cejiang et al. (2005) Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action. Antimicrob Agents Chemother 49:3607-15
Keller, Marla J; Tuyama, Ana; Carlucci, Maria Josefina et al. (2005) Topical microbicides for the prevention of genital herpes infection. J Antimicrob Chemother 55:420-3
John, Minnie; Keller, Marla J; Fam, Ehsan H et al. (2005) Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection. J Infect Dis 192:1731-40
Cheshenko, Natalia; Keller, Marla J; MasCasullo, Veronica et al. (2004) Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread. Antimicrob Agents Chemother 48:2025-36
Keller, M J; Klotman, M E; Herold, B C (2003) Development of topical microbicides for prevention of human immunodeficiency virus and herpes simplex virus. Am J Reprod Immunol 49:279-84

Showing the most recent 10 out of 13 publications